Proxy Results (Form 8-K)

The 2025 Annual Meeting of Stockholders (the "Annual Meeting") of Titan Pharmaceuticals, Inc. (the "Company") was held pursuant to notice on June 16, 2025 at the offices of Olshan Frome Wolosky LLP located at 1325 Avenue of the Americas, 15th Floor, New York, New York 10019. As of the record date, there were 914,234 shares of common stock outstanding and entitled to vote at the Annual Meeting. The total number of shares of common stock voted in person or by proxy at the Annual Meeting was 495,640 shares, representing approximately 54.21% of the shares of common stock outstanding and entitled to vote at the Annual Meeting.

Each director nominee was elected and each other matter submitted to a vote of the Company's stockholders at the Annual Meeting, as described below, was approved by the requisite vote of the Company's stockholders. The final voting results for each of the proposals submitted to a vote of the stockholders of the Company at the Annual Meeting are set forth below. The proposals are described in detail in the Proxy Statement, and are incorporated herein by reference.

Proposal 1 - The election of five directors, to serve until the Company's 2026 annual meeting of stockholders or until their successors are duly elected and qualified.

Proposal 2 - Approval of the issuance of more than 20% of the Company's common stock pursuant to a private placement transaction for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d).

Proposal 3 - Approval of an amendment to the Company's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan (the "2015 Plan") to (i) increase the total number of shares authorized for issuance thereunder and (ii) extend the term of the 2015 Plan by an additional five years.

Proposal 4 - The ratification of Enrome LLP as the Company's independent auditors for the fiscal year ending December 31, 2025.